Patents Assigned to Antisense Therapeutics Ltd.
-
Patent number: 11891606Abstract: A method for treating a patient suffering from multiple sclerosis, including progressive forms of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE I to the patient, thereby treating the patient.Type: GrantFiled: June 15, 2018Date of Patent: February 6, 2024Assignee: Antisense Therapeutics LtdInventor: George Tachas
-
Patent number: 11041156Abstract: A method for mobilizing leukemia cells which are ?4 integrin positive to the peripheral blood of a human subject, the method comprising administering to the human subject an effective amount of an antisense compound to ?4 integrin. The cells may be mobilized from bone marrow. The antisense compound is: 5?-MeCMeUG AGT MeCTG TTT MeUMeCMeC AMeUMeU MeCMeU-3? wherein, (a) each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester; (b) the nucleotides at the positions 1 to 3 from the 5? end are 2?-O-(2-methoxyethyl) modified ribonucleosides; (c) the nucleotides at the positions 4 to 12 from the 5? end are 2?-deoxyribonucleosides; (d) the nucleotides at the positions 13 to 20 from the 5? end are 2?-O-(2-methoxyethyl) modified ribonucleosides; and (e) all cytosines are 5-methylcytosines (MeC), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 4, 2018Date of Patent: June 22, 2021Assignees: Antisense Therapeutics Ltd, Children's Hospital of Los AngelesInventors: George Tachas, Yong-Mi Kim
-
Patent number: 9885048Abstract: The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.Type: GrantFiled: February 17, 2016Date of Patent: February 6, 2018Assignee: Antisense Therapeutic, LtdInventor: George Tachas
-
Patent number: 9821034Abstract: The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.Type: GrantFiled: January 26, 2016Date of Patent: November 21, 2017Assignee: Antisense Therapeutics LtdInventor: George Tachas
-
Patent number: 9717778Abstract: The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.Type: GrantFiled: February 4, 2013Date of Patent: August 1, 2017Assignee: Antisense Therapeutics Ltd.Inventor: George Tachas
-
Patent number: 9371530Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.Type: GrantFiled: December 20, 2013Date of Patent: June 21, 2016Assignee: Antisense Therapeutics Ltd.Inventor: George Tachas
-
Patent number: 9084770Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an IGF-IR mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions that inhibit expression of IGF-IR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate the tumor or cancer, or a symptom thereof.Type: GrantFiled: October 13, 2009Date of Patent: July 21, 2015Assignee: Antisense Therapeutics, Ltd.Inventors: George Tachas, Lynne Maree Atley, Christopher J. Wraight
-
Patent number: 8765700Abstract: A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin ?4 comprising administering to the animal a composition comprising from. 0.001 to 1000 ?g per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin ?4.Type: GrantFiled: October 20, 2005Date of Patent: July 1, 2014Assignee: Antisense Therapeutics Ltd.Inventors: George Tachas, James G. Karras, Susan Gregory, Jeffrey R. Crosby, Kenneth W. Dobie, Frank C. Bennett
-
Patent number: 8637484Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.Type: GrantFiled: October 18, 2012Date of Patent: January 28, 2014Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Ltd.Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
-
Patent number: 8623836Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.Type: GrantFiled: November 23, 2010Date of Patent: January 7, 2014Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Ltd.Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
-
Publication number: 20090286849Abstract: The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory condition.Type: ApplicationFiled: December 22, 2008Publication date: November 19, 2009Applicant: Antisense Therapeutics Ltd.Inventors: Christopher John WRAIGHT, George Arthur Werther, Nicholas M. Dean, Kenneth W. Dobie
-
Publication number: 20090111767Abstract: The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.Type: ApplicationFiled: August 6, 2008Publication date: April 30, 2009Applicant: ANTISENSE THERAPEUTICS LTD.Inventors: Christoper J. WRAIGHT, George A. Werther, Nicholas M. Dean, Kenneth J. Dobie
-
Patent number: 7468356Abstract: The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.Type: GrantFiled: February 11, 2004Date of Patent: December 23, 2008Assignee: Antisense Therapeutics Ltd.Inventors: Cristopher John Wraight, George Arthur Werther, Nicholas M. Dean, Kenneth W. Dobie